1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
First-stage letter of intent deadline was April 23, 2024; full application dates listed as TBD. Stored deadline is null.
NIHR NICE Rolling Funding Opportunity is sponsored by National Institute for Health and Care Research (NIHR). Open NIHR funding opportunity across health and social care.
Get alerted about grants like this
Save a search for “National Institute for Health and Care Research (NIHR)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Hit enter to search or ESC to close Funding Calls Database « All Calls National Institute for Health and Care research UK , NIHR NICE rolling call (EME Programme): The Efficacy and Mechanism Evaluation Programme is accepting Stage 1 applications to this funding opportunity. The programme is interested in receiving applications to meet recommendations in research identified in NICE guidance that has been published or updated since 2015.
Proposals must be within the remit of the EME Programme and the primary outcome measure must be health related. This call is also open in the Health Technology Assessment (HTA), Health and Social Care Delivery Research (HSDR) and Public Health Research (PHR) programmes for proposals which fall within the remit of those programmes – applicants should apply directly to the relevant programme.
All proposals submitted must fall within the scope of the EME Programme. The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments.
EME is a partnership between the Medical Research Council (MRC) and the NIHR. The EME Programme looks to attract studies with novel methodological designs that deliver results more efficiently, reduce the study timeline, and maximise the knowledge gained.
The translational research it supports covers a wide range of new and repurposed interventions, such as diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS. Deadline First stage (LOI / pre-proposal) Deadline Full Application Grant Decision – Final Decision – Awarding Interested in joining this call?
Clinical trial - any phase Other data generation study (e.g. retrospective analysis, case series etc) Pilot study Non-dilutive (grant, donation etc) National Institute for Health and Care research UK The REMEDi4ALL project has received funding from the European Union’s Horizon Europe Research & Innovation programme under grant agreement No 101057442.
About Us REMEDi4ALL is an EU-funded research initiative transforming drug repurposing by building a state-of-the-art platform, uniting global expertise, and accelerating access to cost-effective treatments for patients in need. DEMO PROJECTS To test the platform’s viability and robustness we support real-world projects on infectious diseases, rare cancers, and rare/ultra rare diseases.
i DR The International Drug Repurposing (iDR) Conference Series is an annual global conference series where key opinion leaders from research and patient communities, funders, regulators and representatives from the private sector participate to collectively advance innovative drug repurposing in Europe and beyond.
2026 International Drug Repurposing Conference Medicines Reimagined Newsletter DRUG REPURPOSING CONCIERGE Get expert guidance for your drug repurposing project. Through a 30-minute consultation, our experts help you explore scientific support, regulatory pathways, advocacy opportunities and funding options.
With 250+ inquiries answered and a 100% response rate, the Concierge is your first stop within REMEDi4ALL for navigating the path from discovery to market. PROJECT PARTNERING PORTAL Advance your repurposing project with REMEDi4ALL through a formalised partnership.
Following a thorough evaluation process, selected projects are onboarded to work hand-in-hand with multidisciplinary teams, providing support from early discovery to regulatory approval to patient access. All potential applicants are strongly advised to engage with the Drug Repurposing Concierge before submitting partnering proposals.
REMED i 4ALL Repurposing Academy A range of training resources designed to provide a comprehensive understanding of the drug repurposing landscape. REMEDi4ALL Digital Academy The Digital Academy is our online home for on demand training on repurposing. REMEDi4ALL Bootcamps Our Bootcamps are short, in person training events that provide the chance to meet others in the drug repurposing field.
REMEDi4ALL Webinars Our webinars provide accessible, live training on specific stages of the repurposing journey. REMEDi4ALL Hackathon Join a small team of international trainees to learn on a week-long residential course where you aim to plan the development of a repurposing candidate. Resources We’re a dynamic community dedicated to drug repurposing, we produce a wide range of valuable resources.
Explore our collection here. In-silico Drug Repurposing Catalogue Practical Guide to Creating Joint Funding Calls for Drug Repurposing Research Framework for Judging the Project Value of Repurposed Medicines MEDICINES REIMAGINED Join a vibrant community to connect and collaborate to advance drug repurposing. FUNDERS NETWORK Public and private funders worldwide driving innovation in drug repurposing.
Based on current listing details, eligibility includes: Researchers and institutions involved in health and social care research. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Global Health Research Programmes is sponsored by National Institute for Health and Care Research (NIHR). The NIHR Global Health Research (GHR) portfolio supports applied health research for the direct and primary benefit of people in low and middle income countries (LMICs) on the Organisation for Economic Cooperation and Development (OECD) Development Assistance Committee (DAC) list. This would encompass hematology research in Africa.
The AI Award - Racial and Ethnic Inequalities Call is a grant from the NHS Accelerated Access Collaborative and the National Institute for Health Research that funds development, testing, and evaluation of artificial intelligence technologies addressing racial and ethnic health inequalities within the NHS. The program funds technologies across the full development spectrum from initial feasibility to full NHS-scale evaluation. Phase 1 awards reach up to 150,000 pounds sterling, while Phases 2 through 4 provide up to 7,000,000 pounds sterling for advanced evaluation and implementation. Eligible applicants include academic institutions, NHS trusts, and industry partners developing AI solutions aligned with strategic aims in the NHS Long Term Plan. The program is administered by the NHS AI Lab as part of the broader AI in Health and Care Award initiative.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.